Australian doctors back asthma system, says iSonea

iSonea (ASX:ISN) says 80% of Australian GPs surveyed would recommend its AirSonea mobile wheeze-monitoring system.

As it prepares to debut the system starting with an Australian launch this year, iSonea has contracted US research group Dectiva to help it understand the perceived demand and potential barriers to market launch.

The research firm surveyed 100 Australian doctors involved in asthma treatment, including 50 paediatricians. Both the product and company name were blinded to avoid bias and the survey design was run past two Australian pulmonary experts.

The results show that 80% of GPs and 62% of paediatricians would recommend the system. Respondents considered AirSonea suitable for three out of four asthma patients with unstable conditions who require daily monitoring.

Some respondents felt the need to wait for more clinical data before they would make a recommendation.

The results also highlight asthma treatment practitioners’ frustrations with the traditional methods for home monitoring of asthma - peak flow meters or diaries - due to the low compliance and poor reliability of the results. In March, iSonea unveiled its attempt at solving this problem - a cloud-based asthma data tracking suite.

iSonea shares were trading unchanged at $0.35 as of around 1 pm on Wednesday.